◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY
Home › All stocks › RDY › Revenue

Dr. Reddy's Laboratories Limited (RDY) Revenue 2022–2026

DATA UPDATED 2026-07-21

Dr. Reddy's Laboratories Limited annual revenue for fiscal 2026 was $335.9 billion, an increase of 3.2% from $325.5 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

RDY Annual Revenue

Revenue (annual)2026-03-312025-03-312024-03-312023-03-312022-03-31
Total Revenue$335.9B$325.5B$279.2B$245.9B—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RDY Quarterly Revenue

Revenue (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$75.2B$87.3B$88.1B$85.5B$85.1B—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More RDY metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All RDY financial statements → Interactive RDY charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.